Impact of an HIV budget crisis – modelling HIV infections and mortality in 26 countries

Background International funding for HIV has been critical in reducing new HIV transmissions and deaths. Five countries that account for over 90% of international HIV funding announced reductions in international aid of 10%-70% (20% weighted average) commencing in 2026, and immediate cessation of foreign aid was issued by the US government on 20 January 2025. We investigated the potential impact of these funding reductions on HIV incidence and mortality in 26 countries through mathematical modelling.

Methods We used 26 existing, country-validated Optima HIV models (Albania, Armenia, Azerbaijan, Belarus, Bhutan, Cambodia, Colombia, Costa Rica, Cote d’Ivoire, Dominican Republic, Eswatini, Georgia, Kazakhstan, Kenya, Kyrgyzstan, Malawi, Malaysia, Moldova, Mongolia, Mozambique, South Africa, Sri Lanka, Tajikistan, Uganda, Uzbekistan, Zimbabwe). HIV incidence and HIV-related deaths were projected across 2025-2030 for scenarios with: most recent HIV spending continued (status-quo); anticipated international aid reductions for HIV prevention and testing from five major donor countries; and anticipated international aid reductions plus discontinued President’s Emergency Fund for AIDS Relief (PEPFAR) support for treatment and facility-based testing. Upper and lower bounds reflected different assumptions about mitigation and absorption of funding reductions. Country-specific impacts were based on the proportion of international and PEPFAR funding received.

Findings Across the 26 countries, the 20% reduction in international aid resulted in an 11-71% reduction in HIV prevention and testing spending, and a cumulative additional 0.04 – 1.13 million (1·7%-54·1%) new HIV infections and 0.002 – 0.03 million (0·3%-3·9%) HIV-related deaths across 2025-2030. With PEPFAR support also discontinued, there were an additional 2·47-6·36 million (118·1%-304·8%) new HIV infections and 0·40 - 1·71 million (46·9% - 198·9%) HIV-related deaths across 2025-2030 compared with the status quo. Impacts were greatest in countries with a higher percentage of international funding, and those with increasing incidence among key populations.

Interpretation Unmitigated reductions in international HIV funding could significantly reverse progress by 2030, disproportionately affecting key and vulnerable populations. Establishing sustainable funding mechanisms to safeguard prevention, testing, and care programs is critical to sustaining reductions in incidence and mortality.